EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting E3 ubiquitin ligases to sensitize cancer radiation therapy

Zan Chen, Wei Xu

Precision Radiation Oncology · 2019

DOI: 10.1002/pro6.1069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Precision Radiation Oncology, 2019. Verfasst von Zan Chen und 1 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiotherapy is an effective treatment for many cancer patients to eliminate malignant cells and increase survival rate. However, cancer cells can develop resistance in response to radiation through activation of signaling pathways that promote cell cycle progression, DNA damage response, cell survival, and inflammation. Various combination therapies are developed to sensitize radiotherapy by targeting key signaling proteins involved in radioresponse. The past decade has seen significant advances in the knowledge of ubiquitin signaling in cancer biology. Developing E3 ubiquitin ligase‐related molecules as novel strategies to cure cancer has become an emerging field. This review briefly discusses the potential of targeting diverse E3 ubiquitin ligases as promising strategies for radiosensitization in cancer.

Zitieren

APA

Chen, Z., & Xu, W. (2019). Targeting E3 ubiquitin ligases to sensitize cancer radiation therapy. Precision Radiation Oncology. https://doi.org/10.1002/pro6.1069

Vancouver

Chen Z, Xu W. Targeting E3 ubiquitin ligases to sensitize cancer radiation therapy. Precision Radiation Oncology. 2019. doi:10.1002/pro6.1069

BibTeX
@article{Chen2019,
  author = {Chen, Zan and Xu, Wei},
  title = {Targeting E3 ubiquitin ligases to sensitize cancer radiation therapy},
  journal = {Precision Radiation Oncology},
  year = {2019},
  doi = {10.1002/pro6.1069}
}
Kostenlos starten →